Immutep Ltd has released a press release.
Charles River Laboratories to run IMP761 Toxicology Study
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Immutep
- Publication of Abstracts for ASCO 2023 Annual Meeting
- 1st patient dosed in AIPAC-003 ph2/3 breast cancer trial
- Promising New Data in 1st line NSCLC from INSIGHT-003 Trial
- Excellent initial Overall Survival Benefit in 1st line NSCLC
- FDA supportive of Efti registrational trial in lung cancer
Later from Immutep
- A$80 million fully underwritten equity raising
- Immutep granted US patent for IMP761 agonist LAG-3 antibody
- US patent granted for Efti with PD-1 pathway inhibitor
- 1st Patient Dosed in Phase 2 Soft Tissue Sarcoma Trial
- Immutep receives positive scientific advice from EMA
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep